This diabetes drug will give triple benefits, will take care of kidneys along with sugar and weight

A drug developed to treat diabetes is now proving effective in protecting the kidneys as well. Studies have found that these drugs not only help in weight loss and control blood sugar, but also reduce kidney diseases.

Glucagon-like peptide-1 (GLP-1) receptor agonist drugs developed to treat diabetes are now proving effective in protecting the kidneys as well. In a study, it has been found that these medicines not only help in weight loss and control blood sugar, but also reduce kidney diseases. The research, led by Indian-origin professor Sunil Badwe, was published in The Lancet Diabetes & Endocrinology journal.

The main job of GLP-1 receptor agonists is to control blood sugar. These medicines increase insulin production and reduce blood sugar levels. Along with this, these medicines slow down the digestion process, which reduces appetite and helps in weight loss.

How do these drugs affect the kidneys?

This research found that patients using GLP-1 receptor agonists reduced the risk of kidney failure by 16%. In addition, the glomerular filtration rate that measures kidney function also slows down to 22%. Overall, these drugs reduced the risk of kidney failure, decline in kidney function and death from kidney disease by 19%.

Which GLP-1 receptor agonists were included in the study?

The study involved seven different GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity) and liraglutide (Victoza). In 11 large-scale clinical trials, data was analysed from 85,373 people, of whom 67,769 were people with type-2 diabetes, 17,604 were overweight or obese but did not have diabetes.

According to researchers, chronic kidney disease is a progressive disease that gradually leads to kidney failure and the patient needs dialysis or kidney transplant. This disease is directly related to premature death, especially heart disease. GLP-1 receptor agonists can reduce these problems and improve patients' quality of life.

What's special for patients and doctors?

Professor Sunil Badve said that this effect of GLP-1 receptor agonists is a ray of hope for patients who are battling chronic kidney disease. These medicines not only treat diabetes and obesity but also improve kidney function.

Disclaimer: Dear reader, thank you for reading our news. This news has been written only for the purpose of making you aware. We have taken the help of general information in writing it. If you read anything related to your health anywhere, then definitely consult a doctor before adopting it.